Jazz Pharmaceuticals plc (JAZZ)
JAZZ or CTLT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two companies is the best option for those looking for undervalued stocks?
Wall Street Analysts Believe Jazz (JAZZ) Could Rally 56.66%: Here's is How to Trade
The consensus price target hints at a 56.7% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Jazz Pharmaceuticals (JAZZ) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investing in Jazz (JAZZ)? Don't Miss Assessing Its International Revenue Trends
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View
Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.
Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript
Jazz Pharmaceuticals plc. (NASDAQ:JAZZ ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Andrea Flynn - Vice President and Head-Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renée Galá - President and Chief Operating Officer Rob Iannone - Executive Vice President and Global Head-R&D Phil Johnson - Executive Vice President and Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Marc Goodman - Leerink Jessica Fye - JPMorgan Annabel Samimy - Stifel.
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.30 per share, beating the Zacks Consensus Estimate of $4.68 per share. This compares to earnings of $4.51 per share a year ago.
3 Biotech Stocks to Buy on the Dip: July 2024
The biotechnology sector doesn't need to rizz up investors, as the kids like to say. Unless the human desire to find solutions for vexing conditions and diseases somehow goes away in a dystopian paradigm, the ecosystem is safe.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is The Options Market Predicting A Spike In JAZZ Pharmaceuticals (JAZZ) Stock?
Investors need to pay close attention to JAZZ Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jazz Pharmaceuticals plc's suvecaltamide failed in a phase 2b trial for essential tremor, but this is a minor setback for the company and one that should have been expected. The oxybate franchise is performing well despite generic Xyrem and Lumryz competition, and Jazz is seeing healthy patient and net sales growth of Xywav. Jazz expects to deliver 4% to 9% revenue growth in 2024.
